



A Meeting of the **Borders Area Drugs and Therapeutics Committee** held at 12:30pm on
Wednesday, 25th January 2023 via Microsoft Teams
MINUTE

Present: Dr Kevin Buchan, GP (KB) (Chair of ADTC); Liz Leitch, Formulary Pharmacist (LL); Dr Nicola Henderson, GP (NH); Keith Maclure, Lead Pharmacist Medicines Utilisation (KMacl); Dr Ed James, Consultant Microbiologist (EJ); Andrew Leitch, Lay Member (AL); Kate Warner, Minute Taker (KW)

Item	Situation ; Background; Assessment	Recommendation	Lead	Timescale
1.	Apologies and Announcements: Alison Wilson; Malcolm Clubb; Cathryn Park; Rhona Morrison; Keith Allan; Dr Effie Dearden.			
2.	Declarations of Interest: None			
3.	DRAFT Minute previous meeting			
3.1	Draft minute from 23 rd November 2022 meeting was approved as an accurate record of the meeting with no changes.	Remove draft and upload to internet	KW	26/01/23
4.	Matters Arising			
4.1	Community Hospital Discharge Policy was discussed at previous ADTC meeting and is back to ADTC for final approval after pilot completed and any changes made. KMacl updated ADTC on the completion of two months trial at Haylodge Hospital. There were some teething issues around transfer of prescriptions from surgery to pharmacy with delay and this is being addressed. Working smoothly now and any local tweaks will be finalised. Duns will be next Community Hospital. Data is not available from feedback to pilot at this time and will be circulated. ADTC reviewed the policy and questioned the section on support workers administering insulin, asking what level of training was in place for this. After discussion it was agreed that this should be removed from the policy so that support workers do not administer insulin.	Check and remove the support worker from administering at level 4. Circulate electronically when completed and pilot data available – send to ADTC by email.	KMacl KMacl KW	
5.	NEW MEDICINE APPLICATIONS / NON FORMULARY REQUESTS:			
5.1	ADTC ratified and noted the approved NFRs since previous ADTC meeting for IVIG Grey; Galcanezumab; Streptomycin.	ADTC ratified and noted		

6.	PATIENT & MEDICINES SAFETY:			
6.1	Patient and Medicines Safety Update – Datix Review. RM and CP were not available for the meeting and ADTC felt it would be better for them to be available for the discussion, any comments and any actions to be taken away.	Add to the March ADTC agenda and as regular item.	RM KW	
7.	CLINICAL POLICIES, PROCEDURES and GUIDELINES for APPROVAL:			
7.1	NHS Borders Code of Medicines Policy & Controlled Drug Policy update was discussed and changes reviewed. ADTC agreed that the section on dispensing on page 75 needed clarification. Supply of medicines out of hours section - on containers and labels but not using ward stock. Clarification is needed on what is to be used if ward stock is not to be used. ADTC agreed that the policy could be approved with this change; for update on the Intranet.	ADTC approved with change to be made. Update cover sheet and send CG for upload to intranet	RM KW	
7.2	NHS Borders Flowchart for Medicines Applications was reviewed and approved as update to current flowchart on intranet after all links have been checked. ADTC had a discussion about the use of non-formulary requests locally with an increasing number of queries to complete NFR forms. Non-formulary requests must be done on the appropriate form and be sent to Formulary Pharmacist with evidence. The NFR Panel meet every other month to ADTC and non-formulary drug requested must be appropriate and evidence based. In adopting East Region Formulary, there will be changes expected to prescribing and the increase of NFRs will be monitored along with prescribing changes. There will be a discussion with Primary Care Prescribing Group and ADTC; following which there should be a plan going forward.	ADTC Approved chart Local discussion and plan on NFRs and present to ERFC or agree at PCPG and ADTC – Borders agreement and plan for NFRs.	LL LL – ADTC March agenda	13/03/2023
7.3	Shared Care Agreements (SCAs) ADTC reviewed the documents: Procedure for the development of locally approved Shared Care Agreements (SCAs); Master template for developing SCAs; and Shared Care Guidelines for the Prescribing and Monitoring of Non-Biological Immuno-suppressives and Disease Modifying Drugs for Inflammatory Bowel, Skin and Rheumatic diseases. These papers have had the input from secondary care Specialists, reviewed and updated by GP Sub Group and have been approved by GP Sub Group. ADTC heard about the process when medication is approved by ERFC; clinically appropriate prescribing from secondary and primary care is agreed and then if SCA is appropriate; who is responsible for development and review and then requirement for approval from GP Sub Group. It then goes to ADTC for approval and can be loaded onto Intranet and Ref Help. ADTC discussed NHS Lothian process and East Region collaboration. Also commented on new Right Decision Service (RDS) app and what would be included – do ADTC have any role to play in that new service for accessing clinical documents; approving categories and inclusions.	ADTC Approved. Master documents for SCA development to be added to forms section of Pharmacy intranet site and SCAs to be added to ADTC section of intranet site. Clinical governance to be invited to ADTC - discuss RDS if appropriate.	KW KB/KW	28/02/2023 28/02/2023
7.4	ADTC reviewed the Guidance for the management of elective alcohol detoxification admissions to Huntlyburn Ward and SBAR. ADTC were supportive of intended plan for	ADTC Approved with clarification	LL MC/JT	

	working with BGH team to review current guidance. ADTC requested clarification on:- - in patients with severe liver impairment (page 6 - Benzodiazepines) is it clinically necessary to have both Oxazepam and Lorazepam available? If so should Oxazepam be readily available (stocked in BGH pharmacy and not on any wards). - in management of DTs (page 9) there is a statement that there is no max dose for Benzodiazepines in DTs with the options being Chlordiazepoxide 30-50mg every 1-2 hours or Lorazepam IM 1-2mg. Is there further information on how this works in clinical practice? Is this common practice? Would there be a stage in treatment where referral to a senior colleague would be indicated? ADTC agreed that this was the correct practice and once clarity is received on the points raised are able to approve the guidance. It was noted that Dr Tidder will be working with medics to review detox guidelines in Borders General Hospital.	acceptable on points raised – to be forwarded to ADTC by email.	KW	30/01/2023
7.5	ADTC members, Alison Wilson and Keith Maclure, agreed to be nominated for the Healthcare Improvement Scotland - National Review Panel for PACS Tier Two.	Reply to email to nominate.	AW/KW	30/01/2023
8.	FOR INFORMATION and NOTING:			
8.1	East Region Formulary updates - ERF Committee minute – 30 th November 2022; ERWG minute – 11 th January 2023 (minute not available at time of meeting)	ADTC noted		
8.2	ERF Chapter Updates – Cardiovascular; Endocrine; Infections and Wound Care (all Adult)	ADTC noted		
8.2	Future meetings of ADTC to have a new standing item here – Update to changes and impact on Borders of ERF decisions.	Add to March agenda	KW	13/03/2023
8.3	HEPMA summary of progress	ADTC noted		
9.	FEEDBACK from SUB GROUPS			
9.1	Anticoagulation Committee – no recent meeting			
9.2	Antimicrobial Management Team – meeting 16 th November 2022. EJ provided feedback from OPAT document submitted at November 2022 ADTC meeting – this has been discussed with hospital management and no progress has been made as yet until finance is in place; it has not been submitted to other groups as yet. Penicillin allergy de-labelling has made progress since presenting to ADTC. The new locum in Acute Medicine, J Taylor, is trained in infectious diseases and has agreed to oversee this process in BGH on one to or two patients to begin with. ADTC wished the project well.	ADTC noted		
9.3	Controlled Drug Governance Team – no recent meeting			
9.4	IV Therapy Group – no recent meeting			
9.5	Medicines Resource Group – no recent meeting			
9.6	Non-Medical Prescribing Group – no recent meeting			
9.7	Tissue Viability Steering Group – no recent meeting			
9.8	NHS Lothian ADTC – minute from meeting 7 th October 2022	ADTC noted		

10.	AOCB		
10.1	None		
Date and time of next meeting: Wednesday 22nd March 2023 at 12:30pm via Microsoft Teams.			
Items expected for future Agendas – Summary of ERF chapters (May 2023 - LL); NHS Borders Thematic Review; NHS Borders Extravasation Non SACT Policy (May 2023 – CP); NHS Borders Non-Medical Prescribing Policy update; NHS Borders Steroid Safety Bundle; PCA Pathway (March 2023 – SS)			